SAMIA is an advanced clinical decision support system (CDSS) for Mast Cell Activation Syndrome. Based on artificial intelligence, it offers a structured assessment guide, grounded in the most up-to-date scientific evidence.
Developed with passion by bluemedtech.AI
Project sponsored by Alfasigma Iberia.
SAMIA provides a clinical chatbot designed to assist you in the SAM classification. This AI agent is trained and adjusted periodically to improve the accuracy and clarity of its responses, always functioning as a support tool and never as a substitute for professional clinical judgment.
Sponsored subscriptionThe SAMIA agent works with the same intuitive logic as the diagnostic algorithm, diagnóstico, so you can integrate it into your clinical practice with no learning curve. Navega por las secciones, formula tus dudas y obtén apoyo paso a paso en cuestión de segundos.
Log inA curated collection of key articles and documents about the disease, selected and continuously reviewed by our medical team.
Have a look